ClinicalTrials.gg
RecruitingNCT07904286Updated Oct 29, 2026

Sensory Neurography and S2PD After Digital Nerve Injury

An observational study in Digital Nerve Injury, Sensory Neurography and S2PD, sponsored by Cecilia Mellstrand Navarro. Recruiting at 2 sites in Sweden. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Cecilia Mellstrand Navarro · Observational

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 29, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
60
Ages
20 Years to 60 Years
Sex
All
01

Study summary

The goal of this clinical comparative cross sectional study, is to investigate neurophysiological findings and S2PD (static two point discrimination test) measurements after digital nerve injury.

The main aim is to find out if there are measurable neurophysiological differences in fingers following digital nerve injury that correlate with discriminative sensory function (S2PD) as experienced by the patient. Secondary aim is to investigate how well neurophysiological measurements predict specific S2PD values in the affected fingers.

Participants with a sutured digital nerve injury will be examined with neurophysiology and S2PD testing. Both injured finger and corresponding uninjured finger on the other hand will be examined, i.e participants will be their own control.

Prior to the study the investigators will perform a test-re-test study on ten participants to ensure that the method is reliable (separate registration)

Read the detailed description

The aim of this project is to use neurophysiological assessment to gain a better understanding of what is actually measured by S2PD (static two-point discrimination). A neurophysiological examination can objectively measure any remaining function in an injured digital nerve. Using this method, axons responsible for pressure, vibration, and touch that are still able to conduct an action potential, are assessed.

The response can be measured both as the amplitude of the summed action potentials from the nerve's axons and as the area, which corresponds to the area under the curve formed by the recorded action potentials. The area is a somewhat more precise measurement method, as it includes all axons, both those with low and high conduction velocities. Amplitude measurements may give falsely low values if nerves with poorer degrees of myelination are included in the measurement. Amplitude is measured in µV and area in µV/ms.

The method currently used to assess discriminative sensation, S2PD, is influenced by many external factors, such as the clinician's level of experience, the patient's desire to give the correct answer, language barriers, and similar issues. Furthermore, this examination method does not clarify what is actually being measured beyond the patient's subjective discriminative sensation.

If neurophysiological assessment is used as a complement to S2PD and can provide an objective measurement tool with high reliability and reproducibility, it could become an important addition to the clinical arsenal for follow-up after nerve injury. Such knowledge would make it easier to clinically evaluate, understand, and monitor the healing process of the injured nerve. It would also facilitate the assessment and systematic follow-up of treatment outcomes.

The investigators also believe that patients would benefit from being able to follow nerve healing in a more objective manner, which could help motivate continued training and rehabilitation (such as tactile stimulation, mirror therapy, desensitization, etc.).

Participants will be identified through the national quality register for hand surgery (HAKIR), and will be invited to attend an examination at the Hand Surgery Outpatient Clinic at Sodersjukhuset by phone (postal invitation if no response). If the response rate is low, patients will be contacted by phone one additional time.

The visit, which is estimated to last approximately 60 minutes, will include assessment using static two-point discrimination (S2PD) and neurophysiological examination of the injured finger as well as the corresponding finger on the contralateral, uninjured hand. Sensory assessment with S2PD will be performed on the fingertip pulp, radially or ulnarly, using a discriminator. Sensory thresholds, measured in millimetres, will be recorded in the study protocol.

Finger temperature will be measured using an infrared thermometer (Testo 826-T2), and, if necessary, the fingers will be warmed (using a water bath or heating pad) to a target temperature of a minimum of 32 °C. The hands will then be gently abraded using a preparation gel (NuPrep). Conductive gel (Ten20) will be applied to the electrodes.

A recording electrode will be placed volarly over the wrist, a ground electrode in the palm, and a stimulating electrode on the finger (digits II, III, or IV). Electrical stimulation will be delivered in an orthodromic direction, from the finger toward the wrist. The stimulus intensity will be gradually increased as long as the recorded amplitude continues to rise, up to a maximum of 20% above the intensity at which no further increase in amplitude is observed. This approach ensures inclusion of all excitable axons in the recording, regardless of individual firing thresholds.

02

Conditions studied

  • Digital Nerve Injury
  • Sensory Neurography
  • S2PD

Keywords

  • S2PD
  • Sensory nerve action potential
  • Neurophysiology
  • Static two-point discrimination test
  • Digital nerve injury
  • Sensory neurography
03

In context

Lead sponsor

This is the only study on the registry with Cecilia Mellstrand Navarro as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients treated surgically for a digital nerve injury at the Sodersjukhuset Hand Surgery Clinic from 2013 to 2023.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Injury: One year or more prior to inclusion

Injured finger: digit II, III or radial dig IV

Level of injury: base or middle phalanx

Age at injury>20

Age at inclusion\<60

Exclusion criteria

Exclusion Criteria:

Neurologic disease

Dementia

Cognitive disability

Severe psychiatric disorder (not be able to participate)

Ongoing drug abuse

Not understanding swedish language

History of carpal tunnel syndrome

Negative experience of electric stimulation

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Sensory and neurophysiology outcome in injured digit

    The finger with an injured digital nerve will be examined with S2PD and sensory neurography

    Diagnostic Test: Sensory neurography · Diagnostic Test: Static two point discrimination test, S2PD

  • Sensory and neurophysiology outcome in normal digit

    The contralateral uninjured finger will be examined with S2PD and sensory neurography

    Diagnostic Test: Sensory neurography · Diagnostic Test: Static two point discrimination test, S2PD

Interventions

  • Diagnostic testSensory neurography

    Participants will be examined with sensory neurography (orthodromic stimulation).

  • Diagnostic testStatic two point discrimination test, S2PD

    Participants will be examined with S2PD.

06

What researchers measure

Primary outcomes

  1. Is there a correlation between the amplitude of the sensory nerve action potential and S2PD?

    A potential correlation between the sensory nerve action potential amplitude (microvoltage) measured with sensory neurography and S2PD (in millimeters) measured with a discriminator, will be analysed with test for correlation and presented as a value between -1 and 1

    Time frame: Participant assessments will be conducted during a single session lasting approximately 60 minutes

  2. Is there a correlation between sensory nerve action potential area and S2PD?

    A potential correlation between the sensory nerve action potential area (milliseconds\*microvoltage) measured with sensory neurography and S2PD (in millimeters) measured with a discriminator, will be analysed with test for correlation and presented as a value between -1 and 1

    Time frame: Participant assessments will be conducted during a single session lasting approximately 60 minutes

Secondary outcomes

  1. Does a certain value of S2PD correspond to a specific (percentage) value of the amplitude or area of the action potential?

    We will evaluate the correlation between S2PD (in 1 mm steps) and the percentages of sensory neurography amplitude and area of the injured nerve.

    Time frame: Participant assessments will be conducted during a single session lasting approximately 60 minutes

  2. How does age affect the potential correlation between sensory neurography measures (amplitude and area) and S2PD?

    A regression analysis will be used to evaluate what impact age (years) has on primary outcomes.

    Time frame: Participant assessments will be conducted during a single session lasting approximately 60 minutes

  3. How does participants' sex affect the potential correlation between sensory neurography measures (amplitude and area) and S2PD?

    A regression analysis will be used to evaluate what impact participants' sex (male or female) has on primary outcomes.

    Time frame: Participant assessments will be conducted during a single session lasting approximately 60 minutes

  4. How does smoking affect the potential correlation between sensory neurography measures (amplitude and area) and S2PD?

    A regression analysis will be used to evaluate what impact smoking (yes or no) has on primary outcomes.

    Time frame: Participant assessments will be conducted during a single session lasting approximately 60 minutes

  5. How does the type of injured nerve affect the potential correlation between sensory neurography measures (amplitude and area) and S2PD?

    A regression analysis will be used to evaluate what impact type of injured nerve (digital nerves to second, third or radial side of the fourth finger) has on primary outcomes.

    Time frame: Participant assessments will be conducted during a single session lasting approximately 60 minutes

  6. How does time from injury affect the potential correlation between sensory neurography measures (amplitude and area) and S2PD?

    A regression analysis will be used to evaluate what impact time from injury (in years) has on primary outcomes.

    Time frame: Participant assessments will be conducted during a single session lasting approximately 60 minutes

  7. How does the level of injury affect the potential correlation between sensory neurography measures (amplitude and area) and S2PD?

    A regression analysis will be used to evaluate what impact level of injury (proximal or middle phalanx) has on primary outcomes.

    Time frame: Participant assessments will be conducted during a single session lasting approximately 60 minutes

07

Study locations

1 of 2 sites recruiting
  • Karolinska Institutet Södersjukhuset, Department of clinical research and education
    Stockholm, 11883, Sweden
    Not yet recruiting
  • South General Hospital
    Stockholm, 11883, Sweden
    Recruiting
08

References and documents

Publications

  • https://doi.org/10.1016/S1531-0914(03)00069-X
  • Zanette G, Lauriola MF, Tamburin S. An electrodiagnostic technique for assessing palmar proper digital nerves of the hand: Normative data and clinical application. Muscle Nerve. 2015 Dec;52(6):972-80. doi: 10.1002/mus.24668. Epub 2015 Sep 15. PubMed 25845854 ↗
  • Lundborg G, Rosen B. The two-point discrimination test--time for a re-appraisal? J Hand Surg Br. 2004 Oct;29(5):418-22. doi: 10.1016/j.jhsb.2004.02.008. PubMed 15336741 ↗
  • Wolny T, Linek P. Reliability of two-point discrimination test in carpal tunnel syndrome patients. Physiother Theory Pract. 2019 Apr;35(4):348-354. doi: 10.1080/09593985.2018.1443358. Epub 2018 Feb 26. PubMed 29482409 ↗

Individual participant data

Plan to share: No — Data will be available in pseudonymized form

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2026
First posted
Oct 29, 2026
StartActual
Sep 28, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07904286
Lead sponsor
Cecilia Mellstrand Navarro
Collaborators
Stockholm South General Hospital, AFA Insurance
Responsible party
Cecilia Mellstrand Navarro (MD, PhD, Ass. prof, Karolinska Institutet) — Sponsor-investigator
First posted
Oct 29, 2026
Start date
Sep 28, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 29, 2026

Study contacts

Carin Carlsson, MD
Contact
carin.carlsson@regionstockholm.se
0046812361000
Johanna von Kieseritzky, PhD
Contact
johanna.vonkieseritzky@regionstockholm.se
0046812361000
Cecilia Mellstrand-Navarro, Ass. prof
principal investigator · Karolinska Institutet Södersjukhuset, Department of clinical research and education

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion